HMGCR and ovarian cancer: Pitavastatin treatment induces cell death in ovarian cancer cells in which hydroxymethylglutarate coenzyme-A reductase (HMGCR) is upregulated and TP53 is mutated, and the anti-cancer effect of pitavastatin is solely mediated by the inhibition of HMGCR [89].